- Home
- NMZ vs ELVN Comparison
NMZ vs ELVN Comparison
Compare NMZ & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMZ | ELVN |
|---|---|---|
| Founded | 2003 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NMZ | ELVN |
|---|---|---|
| Price | $10.19 | $15.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $41.00 |
| AVG Volume (30 Days) | 356.8K | ★ 796.1K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 5.08% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.26 | $13.30 |
| 52 Week High | $11.14 | $25.37 |
Technical Indicators
Market Signals| Indicator | NMZ | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 35.50 | 35.13 |
| Support Level | $10.03 | $15.88 |
| Resistance Level | $10.60 | $18.05 |
| Average True Range (ATR) | 0.10 | 1.13 |
| MACD | -0.02 | -0.16 |
| Stochastic Oscillator | 24.54 | 9.68 |
Price Performance
Historical ComparisonAbout NMZ Nuveen Municipal High Income Opportunity Fund $0.01 par value per share
Nuveen Municipal High Income Opp Fund is a diversified, closed-end management investment company. The company's investment objectives is to provide current income exempt from regular federal income tax by investing predominantly in a portfolio of municipal obligations issued by state and local government authorities or certain U.S. territories. It seeks to provide attractive monthly tax-free income, portfolio diversification and attractive after tax total returns. The fund invests in municipal securities that are exempt from federal income taxes.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.